AnaptysBio

1. Jemperli Ph2 readout2H 2026Jemperli Ph2 readout, 2H 2026, notable
2. Corporate Separation updateYear-End 2026Corporate Separation update, Year-End 2026, routine
3. ANB033 Ph1 topline4Q 2026ANB033 Ph1 topline, 4Q 2026, material
4. Post-trial argument litigation rulingOct 20, 2026Post-trial argument litigation ruling, Oct 20, 2026, routine
5. Legal ruling litigationlate 4Q 2026Legal ruling litigation, late 4Q 2026, routine
6. Imsidolimab FDA approvalDec 12, 2026Imsidolimab FDA approval, Dec 12, 2026, material
7. Sagard debt corporate update2Q 2027Sagard debt corporate update, 2Q 2027, routine
8. Sagard non-recourse debt corporate updatelate 2Q 2027Sagard non-recourse debt corporate update, late 2Q 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.